PURPOSE: To determine associations between pretreatment health-related quality of life subscales with progression-free (PFS) and overall survival (OS) in advanced and recurrent cervical cancer. PATIENTS AND METHODS: Patients included those participating in Gynecologic Oncology Group advanced or recurrent cervical cancer phase III treatment trials who completed the Functional Assessment of Cancer Therapy for patients with cervical cancer (FACT-Cx) and a single-item pain scale at study entry. The FACT-Cx includes five domains: physical (PWB), emotional (EWB), social (SWB), functional well being (FWB), and cervix cancer subscale (CCS). A high quality of life (QoL) score reflects better QoL. After stratifying by protocol and adjusting for patient and disease characteristics, a Cox proportional hazards model was fitted for each subscale as a continuous variable. If statistically significant, (p<0.05), an analysis on mean item scores (MIS) was performed. RESULTS: Nine-hundred-ninety-one patients were enrolled from 1997 to 2007. The majority (87%) had recurrent disease. After adjustment for covariates and predictors, only the PWB domain (better physical QoL) was associated with improved OS [HR 0.96 95% CI 0.95-0.98; p<0.001]. When classifying patients based on the MIS of each subscale, the patients with the lowest risk of death were likely to report less compromised QoL (MIS>3) for PWB [HR 0.44 (0.33-0.58) P<0.001], FWB [0.49 (0.38-0.62) P<0.001], and CCS [0.48 (0.38-0.61) P<0.001]. CONCLUSION: The pretreatment patient-reported PWB as measured by the PWB subscale of the FACT-Cx, is significantly associated with survival in advanced cervical cancer trials, even after controlling for known prognostic factors.
PURPOSE: To determine associations between pretreatment health-related quality of life subscales with progression-free (PFS) and overall survival (OS) in advanced and recurrent cervical cancer. PATIENTS AND METHODS: Patients included those participating in Gynecologic Oncology Group advanced or recurrent cervical cancer phase III treatment trials who completed the Functional Assessment of Cancer Therapy for patients with cervical cancer (FACT-Cx) and a single-item pain scale at study entry. The FACT-Cx includes five domains: physical (PWB), emotional (EWB), social (SWB), functional well being (FWB), and cervix cancer subscale (CCS). A high quality of life (QoL) score reflects better QoL. After stratifying by protocol and adjusting for patient and disease characteristics, a Cox proportional hazards model was fitted for each subscale as a continuous variable. If statistically significant, (p<0.05), an analysis on mean item scores (MIS) was performed. RESULTS: Nine-hundred-ninety-one patients were enrolled from 1997 to 2007. The majority (87%) had recurrent disease. After adjustment for covariates and predictors, only the PWB domain (better physical QoL) was associated with improved OS [HR 0.96 95% CI 0.95-0.98; p<0.001]. When classifying patients based on the MIS of each subscale, the patients with the lowest risk of death were likely to report less compromised QoL (MIS>3) for PWB [HR 0.44 (0.33-0.58) P<0.001], FWB [0.49 (0.38-0.62) P<0.001], and CCS [0.48 (0.38-0.61) P<0.001]. CONCLUSION: The pretreatment patient-reported PWB as measured by the PWB subscale of the FACT-Cx, is significantly associated with survival in advanced cervical cancer trials, even after controlling for known prognostic factors.
Authors: David Cella; Viktor Grünwald; Bernard Escudier; Hans J Hammers; Saby George; Paul Nathan; Marc-Oliver Grimm; Brian I Rini; Justin Doan; Cristina Ivanescu; Jean Paty; Sabeen Mekan; Robert J Motzer Journal: Lancet Oncol Date: 2019-01-15 Impact factor: 41.316
Authors: Richard T Penson; Helen Q Huang; Lari B Wenzel; Bradley J Monk; Sharon Stockman; Harry J Long; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J A Reid; Mario M Leitao; Michael Method; Helen Michael; Krishnansu S Tewari Journal: Lancet Oncol Date: 2015-01-29 Impact factor: 41.316
Authors: Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella Journal: Nat Rev Clin Oncol Date: 2015-03-10 Impact factor: 66.675
Authors: Dana M Chase; James Kauderer; Lari Wenzel; Lois Ramondetta; David Cella; Harry J Long; Bradley J Monk Journal: Int J Gynecol Cancer Date: 2015-02 Impact factor: 3.437
Authors: Alaina J Brown; Charlotte C Sun; Diana Urbauer; Donna S Zhukovsky; Charles Levenback; Michael Frumovitz; Premal H Thaker; Diane C Bodurka; Lois M Ramondetta Journal: Support Care Cancer Date: 2014-12-18 Impact factor: 3.603
Authors: Dana Chase; Helen Q Huang; Bradley J Monk; Lois Michelle Ramondetta; Richard T Penson; Karen Gil; Lisa M Landrum; Mario Leitao; Ana Oaknin; Warner K Huh; Heather L Pulaski; Katina Robison; Saketh R Guntupalli; Debra Richardson; Ritu Salani; Michael W Sill; Lari B Wenzel; Krishnansu Sujata Tewari Journal: Int J Gynecol Cancer Date: 2020-02-28 Impact factor: 3.437
Authors: Yu Jung Kim; Mark F Munsell; Ji Chan Park; Larissa A Meyer; Charlotte C Sun; Alaina J Brown; Diane C Bodurka; Janet L Williams; Dana M Chase; Eduardo Bruera; Lois M Ramondetta Journal: Gynecol Oncol Date: 2015-09-30 Impact factor: 5.482